By re-lengthening a shortened RNA, scientists restored the molecular flag that lets immune cells see prostate tumors — turning on checkpoint therapy that usually fails.
Studying human brains — including healthy centenarians — scientists found a moment when microglia switch from helpful to harmful, shaping Alzheimer's outcomes.
A study of a rare fat-loss disorder shows healthy fat tissue is metabolically vital — and when it becomes inflamed and disappears, diabetes can follow.
The deal hands Argenx FB102, an anti-CD122 antibody with early data in vitiligo and celiac disease, deepening its push into autoimmune diseases.
A large real-world analysis eases a lingering worry — that GLP-1 weight loss weakens bones — finding lower fracture rates with semaglutide in type 2 diabetes.
New research suggests oral GLP-1 drugs like orforglipron dial down eating for pleasure — not just hunger — by acting on the brain's reward system.
In 355,000 people, higher coffee intake was linked to sharply lower risks of cirrhosis, liver cancer, and liver-related death — with decaf working too.
A study of older adults with exceptional memory finds their gift can't be explained by lucky Alzheimer's-protective genes, pointing to other factors.
The new nonprescription tablet pairs acetaminophen and naproxen sodium for 12-hour pain relief — the first fixed-dose combo of the two sold over the counter.
JAK inhibitors raise shingles risk, so timing the vaccine matters. A randomized trial found a trade-off between a stronger vaccine response and faster arthritis relief.
Kobe University researchers mass-produced iPSC-derived γδ T cells that cut tumor weight by up to 88% in mice — a step toward cheaper, ready-made cell therapy.
A new analysis explains the paradox: GLP-1 drugs are cost-effective per patient, yet the sheer number of eligible people makes broad coverage financially daunting for insurers.